Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,367
archived clinical trials in
High Blood Pressure (Hypertension)

FK506 (Tacrolimus) in Pulmonary Arterial Hypertension
Single-Center Randomized Controlled Phase II Study of Safety and Efficacy of FK-506 (Tacrolimus) in Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  7/19/2012
Stanford University
mi
from
Stanford, CA
FK506 (Tacrolimus) in Pulmonary Arterial Hypertension
Single-Center Randomized Controlled Phase II Study of Safety and Efficacy of FK-506 (Tacrolimus) in Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 7/19/2012
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT
A Phase I/II, Randomized, Observer-masked, Placebo-and Active-controlled, Parallel-group, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated:  8/1/2012
Santen Investigational Site
mi
from
Newport Beach, CA
A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT
A Phase I/II, Randomized, Observer-masked, Placebo-and Active-controlled, Parallel-group, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated: 8/1/2012
Santen Investigational Site
mi
from
Newport Beach, CA
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT
A Phase I/II, Randomized, Observer-masked, Placebo-and Active-controlled, Parallel-group, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated:  8/1/2012
Santen Investigational Site
mi
from
Deerfield Beach, FL
A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT
A Phase I/II, Randomized, Observer-masked, Placebo-and Active-controlled, Parallel-group, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated: 8/1/2012
Santen Investigational Site
mi
from
Deerfield Beach, FL
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT
A Phase I/II, Randomized, Observer-masked, Placebo-and Active-controlled, Parallel-group, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated:  8/1/2012
Santen Investigational Site
mi
from
Morrow, GA
A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT
A Phase I/II, Randomized, Observer-masked, Placebo-and Active-controlled, Parallel-group, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated: 8/1/2012
Santen Investigational Site
mi
from
Morrow, GA
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT
A Phase I/II, Randomized, Observer-masked, Placebo-and Active-controlled, Parallel-group, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated:  8/1/2012
Santen Investigational Site
mi
from
Rochester, NY
A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT
A Phase I/II, Randomized, Observer-masked, Placebo-and Active-controlled, Parallel-group, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated: 8/1/2012
Santen Investigational Site
mi
from
Rochester, NY
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT
A Phase I/II, Randomized, Observer-masked, Placebo-and Active-controlled, Parallel-group, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated:  8/1/2012
Santen Investigational Site
mi
from
Cleveland, OH
A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT
A Phase I/II, Randomized, Observer-masked, Placebo-and Active-controlled, Parallel-group, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated: 8/1/2012
Santen Investigational Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT
A Phase I/II, Randomized, Observer-masked, Placebo-and Active-controlled, Parallel-group, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated:  8/1/2012
Santen Investigational Site
mi
from
Austin, TX
A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT
A Phase I/II, Randomized, Observer-masked, Placebo-and Active-controlled, Parallel-group, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated: 8/1/2012
Santen Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and Other Safety Parameters.
An Interaction Study to Evaluate Changes in Blood Pressure Following 1, 1.5, 2, and 2.5 mg Riociguat Tid (Dose Titration) Compared to Placebo Treatment on the Background of Stable Sildenafil Pretreatment in Subjects With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  8/28/2012
Clinical Research Facility
mi
from
Aurora, CO
Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and Other Safety Parameters.
An Interaction Study to Evaluate Changes in Blood Pressure Following 1, 1.5, 2, and 2.5 mg Riociguat Tid (Dose Titration) Compared to Placebo Treatment on the Background of Stable Sildenafil Pretreatment in Subjects With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 8/28/2012
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and Other Safety Parameters.
An Interaction Study to Evaluate Changes in Blood Pressure Following 1, 1.5, 2, and 2.5 mg Riociguat Tid (Dose Titration) Compared to Placebo Treatment on the Background of Stable Sildenafil Pretreatment in Subjects With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  8/28/2012
Clinical Research Facility
mi
from
Cleveland, OH
Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and Other Safety Parameters.
An Interaction Study to Evaluate Changes in Blood Pressure Following 1, 1.5, 2, and 2.5 mg Riociguat Tid (Dose Titration) Compared to Placebo Treatment on the Background of Stable Sildenafil Pretreatment in Subjects With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 8/28/2012
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and Other Safety Parameters.
An Interaction Study to Evaluate Changes in Blood Pressure Following 1, 1.5, 2, and 2.5 mg Riociguat Tid (Dose Titration) Compared to Placebo Treatment on the Background of Stable Sildenafil Pretreatment in Subjects With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  8/28/2012
Clinical Research Facility
mi
from
Warwick, RI
Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and Other Safety Parameters.
An Interaction Study to Evaluate Changes in Blood Pressure Following 1, 1.5, 2, and 2.5 mg Riociguat Tid (Dose Titration) Compared to Placebo Treatment on the Background of Stable Sildenafil Pretreatment in Subjects With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 8/28/2012
Clinical Research Facility
mi
from
Warwick, RI
Click here to add this to my saved trials
Blueberry Consumption Improves Vascular Function and Lowers Blood Pressure in Postmenopausal Women With Prehypertension
Daily Incorporation of Blueberries Into a Diet Favorably Improves Vascular Function and Lowers Aortic Blood Pressure in Postmenopausal Women With Prehypertension.
Status: Enrolling
Updated:  9/12/2012
The Department of Nutrition, Food, and Exercise Sciences, The Florida State University
mi
from
Tallahassee, FL
Blueberry Consumption Improves Vascular Function and Lowers Blood Pressure in Postmenopausal Women With Prehypertension
Daily Incorporation of Blueberries Into a Diet Favorably Improves Vascular Function and Lowers Aortic Blood Pressure in Postmenopausal Women With Prehypertension.
Status: Enrolling
Updated: 9/12/2012
The Department of Nutrition, Food, and Exercise Sciences, The Florida State University
mi
from
Tallahassee, FL
Click here to add this to my saved trials
Tolerance to Target Doses of Thiazides in Actual Practice: A Feasibility Study
Tolerance to Target Doses of Thiazides in Actual Practice: A Feasibility Study
Status: Enrolling
Updated:  9/17/2012
Edward Hines,Jr., VA Hospital
mi
from
Hines, IL
Tolerance to Target Doses of Thiazides in Actual Practice: A Feasibility Study
Tolerance to Target Doses of Thiazides in Actual Practice: A Feasibility Study
Status: Enrolling
Updated: 9/17/2012
Edward Hines,Jr., VA Hospital
mi
from
Hines, IL
Click here to add this to my saved trials
Tolerance to Target Doses of Thiazides in Actual Practice: A Feasibility Study
Tolerance to Target Doses of Thiazides in Actual Practice: A Feasibility Study
Status: Enrolling
Updated:  9/17/2012
Charles George VAMC
mi
from
Asheville, NC
Tolerance to Target Doses of Thiazides in Actual Practice: A Feasibility Study
Tolerance to Target Doses of Thiazides in Actual Practice: A Feasibility Study
Status: Enrolling
Updated: 9/17/2012
Charles George VAMC
mi
from
Asheville, NC
Click here to add this to my saved trials
Tolerance to Target Doses of Thiazides in Actual Practice: A Feasibility Study
Tolerance to Target Doses of Thiazides in Actual Practice: A Feasibility Study
Status: Enrolling
Updated:  9/17/2012
Wilkes-Barre VA Medical Center
mi
from
Wilkes-Barre, PA
Tolerance to Target Doses of Thiazides in Actual Practice: A Feasibility Study
Tolerance to Target Doses of Thiazides in Actual Practice: A Feasibility Study
Status: Enrolling
Updated: 9/17/2012
Wilkes-Barre VA Medical Center
mi
from
Wilkes-Barre, PA
Click here to add this to my saved trials
Tolerance to Target Doses of Thiazides in Actual Practice: A Feasibility Study
Tolerance to Target Doses of Thiazides in Actual Practice: A Feasibility Study
Status: Enrolling
Updated:  9/17/2012
WJB Dorn VA Medical Center
mi
from
Columbia, SC
Tolerance to Target Doses of Thiazides in Actual Practice: A Feasibility Study
Tolerance to Target Doses of Thiazides in Actual Practice: A Feasibility Study
Status: Enrolling
Updated: 9/17/2012
WJB Dorn VA Medical Center
mi
from
Columbia, SC
Click here to add this to my saved trials
Tolerance to Target Doses of Thiazides in Actual Practice: A Feasibility Study
Tolerance to Target Doses of Thiazides in Actual Practice: A Feasibility Study
Status: Enrolling
Updated:  9/17/2012
WJB Dorn VAMC/Columbia Orangeburg VA Outpatient Clinic
mi
from
Orangeburg, SC
Tolerance to Target Doses of Thiazides in Actual Practice: A Feasibility Study
Tolerance to Target Doses of Thiazides in Actual Practice: A Feasibility Study
Status: Enrolling
Updated: 9/17/2012
WJB Dorn VAMC/Columbia Orangeburg VA Outpatient Clinic
mi
from
Orangeburg, SC
Click here to add this to my saved trials
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated:  9/18/2012
Novartis Investigative site
mi
from
Los Angeles, CA
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated: 9/18/2012
Novartis Investigative site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated:  9/18/2012
Novartis Investigative Site
mi
from
Miami, FL
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated: 9/18/2012
Novartis Investigative Site
mi
from
Miami, FL
Click here to add this to my saved trials
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated:  9/18/2012
Novartis Investigative Site
mi
from
Chicago, IL
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated: 9/18/2012
Novartis Investigative Site
mi
from
Chicago, IL
Click here to add this to my saved trials
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated:  9/18/2012
Novartis Investigative Site
mi
from
Beach Grove, IN
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated: 9/18/2012
Novartis Investigative Site
mi
from
Beach Grove, IN
Click here to add this to my saved trials
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated:  9/18/2012
Novartis Investigative Site
mi
from
Overland Park, KA
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated: 9/18/2012
Novartis Investigative Site
mi
from
Overland Park, KA
Click here to add this to my saved trials
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated:  9/18/2012
Novartis Investigative Site
mi
from
Louisville, KY
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated: 9/18/2012
Novartis Investigative Site
mi
from
Louisville, KY
Click here to add this to my saved trials
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated:  9/18/2012
Novartis Investigative Site
mi
from
New Orleans, LA
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated: 9/18/2012
Novartis Investigative Site
mi
from
New Orleans, LA
Click here to add this to my saved trials
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated:  9/18/2012
Novartis Investigative Site
mi
from
Rochester, MN
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated: 9/18/2012
Novartis Investigative Site
mi
from
Rochester, MN
Click here to add this to my saved trials
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated:  9/18/2012
Novartis Investigative Site
mi
from
Tupelo, MS
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated: 9/18/2012
Novartis Investigative Site
mi
from
Tupelo, MS
Click here to add this to my saved trials
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated:  9/18/2012
Novartis Investigative Site
mi
from
St Louis, MO
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated: 9/18/2012
Novartis Investigative Site
mi
from
St Louis, MO
Click here to add this to my saved trials
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated:  9/18/2012
Novartis Investigative Site
mi
from
High Point, NC
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated: 9/18/2012
Novartis Investigative Site
mi
from
High Point, NC
Click here to add this to my saved trials
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated:  9/18/2012
Novartis Investigative Site
mi
from
Cincinatti, OH
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated: 9/18/2012
Novartis Investigative Site
mi
from
Cincinatti, OH
Click here to add this to my saved trials
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated:  9/18/2012
Novartis Investigative Site
mi
from
Oklahoma City, OK
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated: 9/18/2012
Novartis Investigative Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated:  9/18/2012
Novartis
mi
from
Portland, OR
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated: 9/18/2012
Novartis
mi
from
Portland, OR
Click here to add this to my saved trials
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated:  9/18/2012
Novartis Investigative Site
mi
from
Blue Bell, PA
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated: 9/18/2012
Novartis Investigative Site
mi
from
Blue Bell, PA
Click here to add this to my saved trials
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated:  9/18/2012
Novartis Investigative Site
mi
from
Knoxville, TN
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated: 9/18/2012
Novartis Investigative Site
mi
from
Knoxville, TN
Click here to add this to my saved trials
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated:  9/18/2012
Novartis Investigative site
mi
from
Dallas, TX
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated: 9/18/2012
Novartis Investigative site
mi
from
Dallas, TX
Click here to add this to my saved trials
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated:  9/18/2012
Novartis Investigative Site
mi
from
Salt Lake City, UT
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated: 9/18/2012
Novartis Investigative Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated:  9/18/2012
Novartis Investigative Site
mi
from
Abingdon, VA
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated: 9/18/2012
Novartis Investigative Site
mi
from
Abingdon, VA
Click here to add this to my saved trials
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated:  9/18/2012
Novartis Investigative Site
mi
from
Spokane, WA
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension
Status: Enrolling
Updated: 9/18/2012
Novartis Investigative Site
mi
from
Spokane, WA
Click here to add this to my saved trials
Study Evaluating the Safety and Intraocular Pressure (IOP) Lowering Response of Brimonidine Tartrate Ophthalmic Solution in Subjects With Open Angle Glaucoma or Ocular Hypertension
A Single-Center, Randomized, Double-Masked, Cross-Over Pilot Study Evaluating Safety and IOP Lowering Response of Brimonidine Tartrate Ophthalmic Solution Versus Vehicle in Subjects With Open Angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated:  9/18/2012
Clinical Site
mi
from
Boston, MA
Study Evaluating the Safety and Intraocular Pressure (IOP) Lowering Response of Brimonidine Tartrate Ophthalmic Solution in Subjects With Open Angle Glaucoma or Ocular Hypertension
A Single-Center, Randomized, Double-Masked, Cross-Over Pilot Study Evaluating Safety and IOP Lowering Response of Brimonidine Tartrate Ophthalmic Solution Versus Vehicle in Subjects With Open Angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated: 9/18/2012
Clinical Site
mi
from
Boston, MA
Click here to add this to my saved trials
Implementation of an Asthma Program to Improve Asthma Identification and Education in Children
Implementation of an Asthma Program to Improve Asthma Identification and Education in Children
Status: Enrolling
Updated:  9/21/2012
Duquesne University
mi
from
Pittsburgh, PA
Implementation of an Asthma Program to Improve Asthma Identification and Education in Children
Implementation of an Asthma Program to Improve Asthma Identification and Education in Children
Status: Enrolling
Updated: 9/21/2012
Duquesne University
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)
A 24 Week, Randomized, Double Blind, Multicenter, Placebocontrolled Efficacy, Safety, Tolerability and PK Trial of Nilotinib (Tasigna®, AMN107) in Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated:  10/1/2012
Novartis Investigative Site
mi
from
Phoenix, AZ
Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)
A 24 Week, Randomized, Double Blind, Multicenter, Placebocontrolled Efficacy, Safety, Tolerability and PK Trial of Nilotinib (Tasigna®, AMN107) in Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated: 10/1/2012
Novartis Investigative Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)
A 24 Week, Randomized, Double Blind, Multicenter, Placebocontrolled Efficacy, Safety, Tolerability and PK Trial of Nilotinib (Tasigna®, AMN107) in Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated:  10/1/2012
Novartis Investigative Site
mi
from
Miami, FL
Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)
A 24 Week, Randomized, Double Blind, Multicenter, Placebocontrolled Efficacy, Safety, Tolerability and PK Trial of Nilotinib (Tasigna®, AMN107) in Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated: 10/1/2012
Novartis Investigative Site
mi
from
Miami, FL
Click here to add this to my saved trials
Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)
A 24 Week, Randomized, Double Blind, Multicenter, Placebocontrolled Efficacy, Safety, Tolerability and PK Trial of Nilotinib (Tasigna®, AMN107) in Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated:  10/1/2012
Novartis Investigative site
mi
from
Boston, MA
Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)
A 24 Week, Randomized, Double Blind, Multicenter, Placebocontrolled Efficacy, Safety, Tolerability and PK Trial of Nilotinib (Tasigna®, AMN107) in Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated: 10/1/2012
Novartis Investigative site
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)
A 24 Week, Randomized, Double Blind, Multicenter, Placebocontrolled Efficacy, Safety, Tolerability and PK Trial of Nilotinib (Tasigna®, AMN107) in Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated:  10/1/2012
Novartis Investigative Site
mi
from
Ann Arbor, MI
Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)
A 24 Week, Randomized, Double Blind, Multicenter, Placebocontrolled Efficacy, Safety, Tolerability and PK Trial of Nilotinib (Tasigna®, AMN107) in Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated: 10/1/2012
Novartis Investigative Site
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)
A 24 Week, Randomized, Double Blind, Multicenter, Placebocontrolled Efficacy, Safety, Tolerability and PK Trial of Nilotinib (Tasigna®, AMN107) in Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated:  10/1/2012
Novartis Investigative Site
mi
from
Rochester, MN
Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)
A 24 Week, Randomized, Double Blind, Multicenter, Placebocontrolled Efficacy, Safety, Tolerability and PK Trial of Nilotinib (Tasigna®, AMN107) in Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated: 10/1/2012
Novartis Investigative Site
mi
from
Rochester, MN
Click here to add this to my saved trials
Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)
A 24 Week, Randomized, Double Blind, Multicenter, Placebocontrolled Efficacy, Safety, Tolerability and PK Trial of Nilotinib (Tasigna®, AMN107) in Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated:  10/1/2012
Novartis Investigative Site
mi
from
High Point, NC
Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)
A 24 Week, Randomized, Double Blind, Multicenter, Placebocontrolled Efficacy, Safety, Tolerability and PK Trial of Nilotinib (Tasigna®, AMN107) in Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated: 10/1/2012
Novartis Investigative Site
mi
from
High Point, NC
Click here to add this to my saved trials
Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)
A 24 Week, Randomized, Double Blind, Multicenter, Placebocontrolled Efficacy, Safety, Tolerability and PK Trial of Nilotinib (Tasigna®, AMN107) in Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated:  10/1/2012
Novartis Investigative Site
mi
from
Cincinatti, OH
Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)
A 24 Week, Randomized, Double Blind, Multicenter, Placebocontrolled Efficacy, Safety, Tolerability and PK Trial of Nilotinib (Tasigna®, AMN107) in Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated: 10/1/2012
Novartis Investigative Site
mi
from
Cincinatti, OH
Click here to add this to my saved trials
Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)
A 24 Week, Randomized, Double Blind, Multicenter, Placebocontrolled Efficacy, Safety, Tolerability and PK Trial of Nilotinib (Tasigna®, AMN107) in Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated:  10/1/2012
Novartis Investigative Site
mi
from
Knoxville, TN
Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)
A 24 Week, Randomized, Double Blind, Multicenter, Placebocontrolled Efficacy, Safety, Tolerability and PK Trial of Nilotinib (Tasigna®, AMN107) in Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated: 10/1/2012
Novartis Investigative Site
mi
from
Knoxville, TN
Click here to add this to my saved trials
Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)
A 24 Week, Randomized, Double Blind, Multicenter, Placebocontrolled Efficacy, Safety, Tolerability and PK Trial of Nilotinib (Tasigna®, AMN107) in Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated:  10/1/2012
Novartis Investigative site
mi
from
Dallas, TX
Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)
A 24 Week, Randomized, Double Blind, Multicenter, Placebocontrolled Efficacy, Safety, Tolerability and PK Trial of Nilotinib (Tasigna®, AMN107) in Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated: 10/1/2012
Novartis Investigative site
mi
from
Dallas, TX
Click here to add this to my saved trials
Assessmet of Patients With PAH Right Ventricular Volume
Assessment of Right Ventricular Volume Using the Ventripoint Medical System in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  10/5/2012
University of Chicago
mi
from
Chicago, IL
Assessmet of Patients With PAH Right Ventricular Volume
Assessment of Right Ventricular Volume Using the Ventripoint Medical System in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 10/5/2012
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Assessmet of Patients With PAH Right Ventricular Volume
Assessment of Right Ventricular Volume Using the Ventripoint Medical System in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  10/5/2012
Brigham and Women's Hosp
mi
from
Boston, MA
Assessmet of Patients With PAH Right Ventricular Volume
Assessment of Right Ventricular Volume Using the Ventripoint Medical System in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 10/5/2012
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Assessmet of Patients With PAH Right Ventricular Volume
Assessment of Right Ventricular Volume Using the Ventripoint Medical System in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  10/5/2012
Mayo Clinic Rochester
mi
from
Rochester, MN
Assessmet of Patients With PAH Right Ventricular Volume
Assessment of Right Ventricular Volume Using the Ventripoint Medical System in Patients With Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 10/5/2012
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials